Form 4: Corcept Therapeutics Executive William Guyer Executes Stock Option and Sells Shares Under 10b5-1 Plan

William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold 30,000 shares of common stock on May 28, 2024, according to a Form 4 filing with the SEC.

Summary

• On May 28, 2024, William Guyer, the Chief Development Officer of Corcept Therapeutics, exercised stock options to acquire 30,000 shares of common stock at a price of $19.26 per share.
• Simultaneously, Guyer sold 30,000 shares of Corcept Therapeutics common stock at $32 per share.
• The sale was executed under a pre-arranged 10b5-1 trading plan.
• Following these transactions, Guyer directly owns 6,039 shares of Corcept Therapeutics common stock.
• This includes 478 shares underlying unvested restricted stock awards and 609 shares underlying unvested restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. The use of a 10b5-1 plan suggests the transactions were pre-planned and intended to avoid accusations of insider trading.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's prospects. The use of a 10b5-1 plan suggests the transactions were pre-planned and intended to avoid accusations of insider trading.

Stakeholder Impact

• The transaction could have a minor impact on shareholders, depending on how the market interprets the insider's actions.

Key Dates